Partneringdesk deals and alliances in blood and lymphatic diseases provides an in-depth view of over 600 deals and alliances announced in blood and lymphatic diseases between 2001 and 2006, in a clear ...
Snapshots International | 13 pages | June 2005 | English
Snapdata's US Eye & Contact Lens Care 2005 report provides 2004 year-end market data, with 2005 estimates and five-year forecasts. The report gives an instant overview of the US eye and contact len ...
IntroductionAdolor, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the management of opioid-related side effects and pain. Entereg, the company's ...
A Partneringdesk Deals Briefing provides an in-depth view of all the deals made by the company and its subsidiaries between 2001 and 2006, in a clear and accessible PDF format.Chapter 1: Company profi ...
Datamonitor's Biogen Idec, Inc. - SWOT Analysis company profile is the essential source for top-level company data and information. The report examines the companys key business structure and ...
Snapshots International | 11 pages | November 2007 | English
L'étude Snapshots Etats Unis Traitement de l'acné 2007, publiée par Snapshots dans le serie Automédication, est disponible uniquement en Anglais pour le moment. Néanmoins, bien que chacun de nos t ...
Datamonitor's Generics in Japan industry profile is an essential resource for top-level data and analysis covering the generics industry. It includes detailed data on market size and segmentation, ...
Datamonitor's Global Life Sciences Tools & Services global life sciences tools & services industry. It includes detailed data on market size and segmentation, plus textual analysis of the key tren ...
Datamonitor's Daiichi Sankyo Co., Ltd. - SWOT Analysis company profile is the essential source for top-level company data and information. The report examines the companys key business structu ...
Report overviewThe success of protein and peptide therapeutics is revolutionizing the biotech and pharmaceutical market, spurring the creation of next-generation products with reduced immunogenicity, ...